London
· Delayed Price · Currency is GBP · Price in USD Mereo BioPharma Group Statistics
Total Valuation
Mereo BioPharma Group has a market cap or net worth of GBP 375.10 million. The enterprise value is 315.69 million.
| Market Cap | 375.10M |
| Enterprise Value | 315.69M |
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +12.61% |
| Shares Change (QoQ) | +8.20% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 100.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 7.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.34 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.10, with a Debt / Equity ratio of 0.09.
| Current Ratio | 6.10 |
| Quick Ratio | 5.83 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.24 |
Financial Efficiency
Return on equity (ROE) is -62.11% and return on invested capital (ROIC) is -28.94%.
| Return on Equity (ROE) | -62.11% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -28.94% |
| Return on Capital Employed (ROCE) | -51.07% |
| Revenue Per Employee | 22,609 |
| Profits Per Employee | -1.02M |
| Employee Count | 33 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.32% in the last 52 weeks. The beta is 0.97, so Mereo BioPharma Group's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | -24.32% |
| 50-Day Moving Average | 3.41 |
| 200-Day Moving Average | 3.72 |
| Relative Strength Index (RSI) | 45.10 |
| Average Volume (20 Days) | 3,911 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.93 |
Income Statement
In the last 12 months, Mereo BioPharma Group had revenue of GBP 746,100 and -33.81 million in losses. Loss per share was -0.23.
| Revenue | 746,100 |
| Gross Profit | 949,785 |
| Operating Income | -28.40M |
| Pretax Income | -34.21M |
| Net Income | -33.81M |
| EBITDA | -27.96M |
| EBIT | -28.40M |
| Loss Per Share | -0.23 |
Balance Sheet
The company has 60.08 million in cash and 4.98 million in debt, giving a net cash position of 55.09 million.
| Cash & Cash Equivalents | 60.08M |
| Total Debt | 4.98M |
| Net Cash | 55.09M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 54.12M |
| Book Value Per Share | 0.35 |
| Working Capital | 54.10M |
Cash Flow
| Operating Cash Flow | -22.53M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 127.30% |
| Operating Margin | -3,806.60% |
| Pretax Margin | -4,584.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Mereo BioPharma Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.61% |
| Shareholder Yield | -12.61% |
| Earnings Yield | -9.01% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Mereo BioPharma Group has an Altman Z-Score of 9.32.
| Altman Z-Score | 9.32 |
| Piotroski F-Score | n/a |